BTIG Reiterates a Buy Rating on Viking Therapeutics (VKTX) With a $125 PT

Core Viewpoint - Viking Therapeutics, Inc. (NASDAQ:VKTX) is identified as a strong buy stock by Wall Street, with a price target set at $125.00 by BTIG analyst Justin Zelin [1][2]. Company Position - Viking Therapeutics is well-positioned in the obesity and metabolic disease market, which is underscored by recent acquisitions in the sector, such as Pfizer's acquisition of Metsera, indicating the high valuation and strategic importance of companies in this field [2]. - The company is recognized as one of the few remaining independent players in the industry with an advanced and mature portfolio, making it an attractive target for potential acquisitions or partnerships [3]. Industry Context - Viking Therapeutics operates as a clinical-stage company focused on developing therapies for metabolic and endocrine disorders, highlighting its relevance in a growing market [4].